Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 4/20 | 0.69 |
| ▸ | NPY2R | P49146 | 1/20 | 0.69 |
| ▸ | NPY4R | P50391 | 1/20 | 0.69 |
| ▸ | MC4R | P32245 | 2/20 | 0.59 |
| ▸ | MC3R | P41968 | 2/20 | 0.59 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.57 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.57 |
| ▸ | C3AR1 | Q16581 | 3/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D[-Arg-2]Kyotorphan Acetate SCHEMBL31332230 | 1.00 | NPY1R (0.69) | NPY1RNPY2RNPY4RMC4RMC3R | |
| Kyotorphin SCHEMBL29516637 | 1.00 | NPY1R (0.69) | NPY1RNPY2RNPY4RMC4RMC3R | |
| Kyotorphin SCHEMBL29966938 | 1.00 | NPY1R (0.69) | NPY1RNPY2RNPY4RMC4RMC3R | |
| SCHEMBL29471109 | 0.91 | MC4R (0.67) | NPY1RNPY2RNPY4RMC4RMC3R | |
| SCHEMBL29936161 | 0.89 | NPY4R (0.69) | NPY1RNPY2RNPY4RNPFFR1NPFFR2 | |
| SCHEMBL29351314 | 0.88 | MC4R (0.65) | NPY1RNPY2RNPY4RMC4RMC3R | |
| SCHEMBL29360943 | 0.88 | NPY1R (0.60) | NPY1RNPY2RNPY4RMC4RMC3R | |
| SCHEMBL29349984 | 0.85 | NPY1R (0.65) | NPY1RNPY2RNPY4RMC4RMC3R | |
| SCHEMBL29350671 | 0.85 | NPY1R (0.73) | NPY1RNPY2RNPY4RERAP2ERAP1 | |
| SCHEMBL29406227 | 0.84 | LNPEP (0.61) | NPY1RNPY2RNPY4RERAP2LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1773 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038846-A1 | L-ARGININE FORMULATIONS AND METHODS OF MANAGING PAIN | EMORY UNIVERSITY (US) | 2025-02-20 | — | — | WO | claimed |
| CN-119326868-A | Ginseng antler refined component and preparation method and application thereof | 长春中医药大学 | 2025-01-21 | — | — | CN | claimed |
| CN-119119173-A | Kyotrophin synthesis method | 湖北泓肽生物科技有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-112638423-B | Bioconjugates of neuropeptide derivatives | 法国国家科学研究中心 | 2024-10-25 | — | — | CN | claimed |
| CN-114920851-B | Aβ1-42 antigen and use thereof for detecting Aβ1-42 concentration in Alzheimer's patient | 福建亿彤生物科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-118067865-A | Quantitative detection method for middle ear cholesteatoma tissue differential markers | 浙江大学 | 2024-05-24 | — | — | CN | claimed |
| CN-118032972-A | Screening method of middle ear cholesteatoma bone-breaking progress related metabolites | 浙江大学 | 2024-05-14 | — | — | CN | claimed |
| US-11845055-B2 | Swellable organically modified silica as nanoreactors | APPALACHIAN STATE UNIVERSITY (US) | 2023-12-19 | — | — | US | claimed |
| CN-115806946-A | Preparation method of kyotorphin and derivatives thereof | 深圳瑞德林生物技术有限公司 | 2023-03-17 | — | — | CN | claimed |
| US-11590232-B2 | Bioconjugates of neuropeptides derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-02-28 | — | — | US | claimed |
| US-5624894-A | Brain-enhanced delivery of neuroactive peptides by sequential metabolism | UNIVERSITY OF FLORIDA (US) | 1997-04-29 | — | — | US | claimed |
| EP-0661986-A4 | BRAIN-ENHANCED DELIVERY OF NEUROACTIVE PEPTIDES BY SEQUENTIAL METABOLISM. | UNIV FLORIDA (US) | 1997-04-23 | — | — | EP | claimed |
| WO-1997003652-A1 | EPIDURAL ADMINISTRATION OF THERAPEUTIC COMPOUNDS WITH SUSTAINED RATE OF RELEASE | DEPOTECH CORPORATION (US) | 1997-02-06 | — | — | WO | claimed |
| EP-0709085-A1 | Sustained-release preparation | Takeda Chemical Industries, Ltd. (JP) | 1996-05-01 | — | — | EP | claimed |
| EP-0661986-A1 | BRAIN-ENHANCED DELIVERY OF NEUROACTIVE PEPTIDES BY SEQUENTIAL METABOLISM | UNIVERSITY OF FLORIDA (US) | 1995-07-12 | — | — | EP | claimed |
| WO-1994006450-A1 | BRAIN-ENHANCED DELIVERY OF NEUROACTIVE PEPTIDES BY SEQUENTIAL METABOLISM | UNIVERSTIY OF FLORIDA (US) | 1994-03-31 | — | — | WO | claimed |
| WO-1993024150-A1 | SALTS OF PEPTIDES WITH CARBOXY-TERMINATED POLYESTERS | ZENECA LIMITED (GB) | 1993-12-09 | — | — | WO | claimed |
| EP-0540631-A1 | TRANS-MUCOSAL DRUG PREPARATIONS AND TRANS-MUCOSAL ADMINISTRATION | Rijksuniversiteit te Leiden (NL) | 1993-05-12 | — | — | EP | claimed |
| EP-0506032-A1 | Receptor purification method | AMERICAN CYANAMID COMPANY (US) | 1992-09-30 | — | — | EP | claimed |
| WO-1992001440-A1 | TRANS-MUCOSAL DRUG PREPARATIONS AND TRANS-MUCOSAL ADMINISTRATION | RIJKSUNIVERSITEIT TE LEIDEN (NL) | 1992-02-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845055-B2 | Swellable organically modified silica as nanoreactors | MSN, SORD, OGA | NPY1R 4768/4885NPY2R 4799/4885NPY4R 4617/4885 |
| US-11590232-B2 | Bioconjugates of neuropeptides derivatives | VIP, NGLY1, NPSR1 | NPY1R 42/4885NPY2R 71/4885NPY4R 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.